Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, recently published a series of three papers on investigating the risk of acute liver failure (ALF) following systemic administration of quinolones, based on a synthesis of evidence from available clinical trials, the US FDA Adverse Event Reporting System (FAERS), and a large US database of electronic health records (EHR).
Although clinical trials provided little evidence of an increased risk, there were reports in FAERS of quinolone-linked ALF cases. Although the primary EHR analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
Posted in RSI News
More RSI News
Climate change modelling for the Bow River watershed
Developing a suite of watershed-scale climate models.
Read News ItemQuarterWatch analyzes MedWatch Reports
This issue of QuarterWatch analyzes MedWatch Reports from the third quarter of 2015. This issue identifies major differences in reports of cancer associated with drugs…
Read News Item